Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. has received two drug registration certificates for Dabigatran Etexilate Capsules from the National Medical Products Administration [1] Group 1: Product Approval - Tianfang Pharmaceutical received approval for Dabigatran Etexilate Capsules in two specifications: 150mg and 110mg [1] - Dabigatran Etexilate is a direct thrombin inhibitor used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1] Group 2: Indications and Uses - The drug is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) [1] - It also helps lower the risk of recurrence of DVT and PE, and is used for the prevention of DVT and PE following hip replacement surgery [1]

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd., received two drug registration certificates for Dabigatran Etexilate Capsules from the National Medical Products Administration, which is expected to enhance the company's product line and provide valuable experience for future generic drug development [1] Group 1 - The drug Dabigatran Etexilate is a direct thrombin inhibitor used primarily to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treat deep vein thrombosis and pulmonary embolism, and lower the risk of recurrence of these conditions [1] - The approval of Dabigatran Etexilate Capsules will enrich the company's product matrix and further improve its product layout [1] - The experience gained from this approval will be beneficial for the company's future generic drug development [1]

Core Viewpoint - The company Tianfang Pharmaceutical, a wholly-owned subsidiary of China Pharmaceutical, has received approval from the National Medical Products Administration for two drug registration certificates for Dabigatran Etexilate Capsules, indicating a significant advancement in its product pipeline [1] Group 1 - The National Medical Products Administration accepted the registration application for the drug in May 2024 [1] - The total investment in the raw materials and formulation projects for this drug has reached approximately 28 million RMB (unaudited) [1]

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd., has received two drug registration certificates for Dabigatran Etexilate Capsules from the National Medical Products Administration, which is expected to enhance the company's product line and provide valuable experience for future generic drug development [1] Group 1 - The drug Dabigatran Etexilate is a direct thrombin inhibitor used primarily to reduce the risk of stroke and systemic embolism in non-valvular atrial fibrillation, treat deep vein thrombosis and pulmonary embolism, and lower the risk of recurrence of these conditions [1] - The approval of Dabigatran Etexilate Capsules will enrich the company's product matrix and further improve its product layout [1] - The experience gained from this approval will be beneficial for the company's future generic drug development [1]

转自：前瞻产业研究院 以下数据及分析来自于前瞻产业研究院医药研发外包(CRO)研究小组发布的《中国医药研发外包 （CRO）行业市场前瞻与投资战略规划分析报告》。 行业主要上市公司：目前国内CRO行业主要的上市公司有药明康德(603259.SH)、康龙化成 (300759.SZ)、泰格医药(300347.SZ)、凯莱英(002821.SZ)、昭衍新药(603127.SH)、九洲药业 (603456.SH)、皓元医药(688131.SH)、博腾股份(300363.SZ)、成都先导(688222.SH)、药石科技 (300725.SZ)等。 本文核心数据： 企业主营业务收入 1、药明康德在中国CRO市场份额占比约四分之一 根据2024年中国CRO行业的企业营收份额占比情况可见，药明康德以将近四分之一的市场份额、290亿 元营收，在中国CRO市场中稳居绝对龙头地位，其市场占比不仅远超康龙化成、泰格医药等头部同 行，营收规模更是大幅领先，凭借显著的规模优势与竞争壁垒，成为引领行业发展的核心主导力量。 2、药明康德发展历程概览 3、药明康德营收爆发式增长，持续保持高位 根据企业公布的近五年营收数据，2020至2022年， ...

内容概要：医药终端指的是药品被消费者购买的市场。医药工业是关系国计民生和国家安全的重要产 业。我国是世界工业医药大国，产业链完整，医药产品品种数量、生产能力位居全球前列。近年来，我 国医药工业高质量发展成效显著，医药终端是药品流通的最终交付环节在中国医药市场的广阔天地中， 长久以来，第一终端（公立医院）与第二终端（零售药店）一直占据着舞台的中心。中国药品终端市场 近年来总体保持稳定增长，但增速有所放缓。2025年前三季度，我国医药三大终端六大市场药品销售总 额达到13924亿元，其中，对公立医院终端药品销售额8290亿元，占终端销售额的59.5%；对零售药店 终端药品销售额4385亿元，占终端销售额的31.5%；对公立基层医疗终端药品销售额1249亿元，占终端 销售额的9.0%。 上市企业：益丰药房[603939]、一心堂[002727]、大参林[603233]、老百姓[603883]、漱玉平民 [301017]、健之佳[605266]、达嘉维康 [301126]、华人健康[301408] 2018-2025年前三季度中国医药三大终端六大市场药品销售总额 在中国医药市场的广阔天地中，长久以来，第一终端（公立医 ...

1月21日晚间，中国医药（600056.SH）发布公告，详细回复上交所对其拟现金收购上海则正医药70%股 权的监管问询。标的公司业绩剧烈波动、估值高企、业务转型风险与整合难题逐一曝光，而中国医药自 身亦面临业绩连年下滑、现金流紧绷、治理风波不断的困境，此次并购能否真正提振公司竞争力，仍存 诸多疑问。 01标的公司业绩"过山车"，技术转让依赖症隐现 上海则正医药主营药品研发服务及技术成果转化。2024年至2025年，其业绩上演"过山车"：2024年营收 约2.57亿元，净利润3933.61万元；2025年1 9月营收骤降至1.07亿元，净利润亏损4084.78万元。尽管全 年最终实现扭亏，净利润944.47万元，但同比仍暴跌75.99%。 值得关注的是，标的公司2025年第四季度单季盈利高达5029.25万元，贡献全年全部利润并弥补前三季 度亏损，呈现明显的"年底突击"特征。公司解释称，四季度增长主要来自技术转让签约客户的转化与订 单签署。 业务结构风险同步暴露：2025年，其药学研究业务收入同比下降66.87%，CRO业务收入下滑46.44%， 新签订单金额减少30.81%。相反，技术转让业务收入同比增长10 ...

证券日报网讯 1月29日，中国医药发布公告称，公司下属全资子公司海南通用三洋药业有限公司收到国 家药品监督管理局核准签发的两份注射用赖氨匹林《药品补充申请批准通知书》，该药品通过仿制药质 量和疗效一致性评价。 （编辑 袁冠琳） ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.22% on January 29, with Renmin Tongtai leading the drop [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] Stock Performance - Notable gainers in the pharmaceutical sector included: - Run Da Medical (603108) with a closing price of 16.43, up 2.88% and a trading volume of 455,600 shares, totaling 756 million yuan [1] - Da Shen Lin (603233) closed at 20.25, up 2.27% with a trading volume of 84,100 shares, totaling 170 million yuan [1] - Hua Ren Health (301408) closed at 22.35, up 0.81% with a trading volume of 267,500 shares, totaling 602 million yuan [1] - Major decliners included: - Renmin Tongtai (600829) closed at 11.77, down 4.70% with a trading volume of 301,800 shares, totaling 357 million yuan [2] - Hai Wang Biological (000078) closed at 3.80, down 4.04% with a trading volume of 2,002,500 shares, totaling 771 million yuan [2] - Rui Kang Pharmaceutical (002589) closed at 3.40, down 2.86% with a trading volume of 757,500 shares, totaling 260 million yuan [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 310 million yuan from major funds, while retail investors contributed a net inflow of 388 million yuan [2] - The detailed capital flow for selected stocks showed: - Run Da Medical had a net inflow of 61.41 million yuan from major funds, but a net outflow of 44.17 million yuan from retail investors [3] - Kyushu Tong (600998) experienced a net inflow of 20.92 million yuan from major funds, with a net outflow of 7.80 million yuan from retail investors [3] - Other stocks like Da Shen Lin and Lao Bai Xing also showed mixed capital flows with varying degrees of net inflows and outflows [3]

证券代码：600056 证券简称：中国医药 公告编号：临 2026-010 号 中国医药健康产业股份有限公司 通知书编号：2026B00478、2026B00479 关于子公司获得药品补充申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司海南通用三洋药业有限公司（以下简称"三洋药业"）收到国家药品监督管理 局（以下简称"国家药监局"）核准签发的两份注射用赖氨匹林（以下简称"该 药品"）《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评 价。现将有关情况公告如下： 一、药品补充申请批准通知书基本信息 剂型：注射剂 规格：0.9g、1.8g 药品名称：注射用赖氨匹林 受理号：CYHB2450545、CYHB2450546 经查询国家药监局网站显示，截至本公告披露日，除三洋药业外，国内已有 重庆药友制药有限责任公司、吉林敖东洮南药业股份有限公司、蚌埠丰原涂山制 药有限公司等 6 家企业通过或视同通过该药品的一致性评价。 根据第三方米 ...